⚠ Evidence note: Direct MPN evidence on lifestyle factors is limited; this synthesis draws heavily on adjacent literature.
Curcumin Supplementation
Current understanding
Curcumin is a polyphenol from turmeric with known anti-inflammatory activity in vitro and in non-MPN inflammatory conditions (mechanism-plausible). A phase II trial (C3 complex/Bioperine) is currently evaluating curcumin in CCUS, low-risk MDS, and MPN patients for reduction of inflammatory markers and symptom burden — results pending, so no mpn-direct outcome evidence exists yet (trial-early, would upgrade to mpn-direct on readout). No recommendation can be made at this time.
Evidence log
- 2026-03-10 — An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms: cross-connection with n-acetylcysteine-supplementation: Both are supplement/antioxidant interventions in active MPN trials targeting inflammation/oxidative-stress pathways; useful to track in parallel as the early antioxidant-supplement evidence base for MPN. (novelty: 3)
Open questions
Related
Contributing findings
Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms
27-mar-2026
novelty 3
per-area 3
introduces